These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 36121916)
1. Identification of super-enhancer-associated transcription factors regulating glucose metabolism in poorly differentiated thyroid carcinoma. Liu K; Du Y; Li H; Lin X Genet Mol Biol; 2022; 45(3):e20210370. PubMed ID: 36121916 [TBL] [Abstract][Full Text] [Related]
2. Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target? Wächter S; Di Fazio P; Maurer E; Manoharan J; Keber C; Pfestroff A; Librizzi D; Bartsch DK; Luster M; Eilsberger F Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830843 [TBL] [Abstract][Full Text] [Related]
4. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma. Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630 [No Abstract] [Full Text] [Related]
5. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332 [TBL] [Abstract][Full Text] [Related]
6. Identification of Potential Pathogenic Super-Enhancers-Driven Genes in Pulmonary Fibrosis. Li H; Zhao C; Li Z; Yao K; Zhang J; Si W; Liu X; Jiang Y; Zhu M Front Genet; 2021; 12():644143. PubMed ID: 34054916 [TBL] [Abstract][Full Text] [Related]
7. Screening and cellular validation of prognostic genes regulated by super enhancers in oral squamous cell carcinoma. Zhang L; Li H; Qiu Y; Liu Y; Liu X; Wang W Bioengineered; 2021 Dec; 12(2):10073-10088. PubMed ID: 34709988 [TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Pita JM; Banito A; Cavaco BM; Leite V Br J Cancer; 2009 Nov; 101(10):1782-91. PubMed ID: 19809427 [TBL] [Abstract][Full Text] [Related]
9. The molecular understanding of super-enhancer dysregulation in cancer. Yoshino S; Suzuki HI Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935 [TBL] [Abstract][Full Text] [Related]
10. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508 [TBL] [Abstract][Full Text] [Related]
11. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer. Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of neutrophil-to-lymphocyte ratio for long-term outcomes in patients with poorly differentiated thyroid cancer. Oba T; Maeno K; Amitani M; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Uehara T; Ito KI Endocr J; 2021 Nov; 68(11):1329-1336. PubMed ID: 34219074 [TBL] [Abstract][Full Text] [Related]
13. Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. Hah N; Benner C; Chong LW; Yu RT; Downes M; Evans RM Proc Natl Acad Sci U S A; 2015 Jan; 112(3):E297-302. PubMed ID: 25564661 [TBL] [Abstract][Full Text] [Related]
14. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Wong KS; Dong F; Telatar M; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Afkhami M; Barletta JA Thyroid; 2021 Jun; 31(6):933-940. PubMed ID: 33143568 [No Abstract] [Full Text] [Related]
15. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400 [TBL] [Abstract][Full Text] [Related]
16. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Soares P; Lima J; Preto A; Castro P; Vinagre J; Celestino R; Couto JP; Prazeres H; Eloy C; Máximo V; Sobrinho-Simões M Curr Genomics; 2011 Dec; 12(8):609-17. PubMed ID: 22654560 [TBL] [Abstract][Full Text] [Related]
17. [Research progress in poorly differentiated thyroid carcinoma]. Chen H; Feng T; Li X; Wang Z Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 39(10):1083-7. PubMed ID: 25355270 [TBL] [Abstract][Full Text] [Related]
18. Enhancer RNAs: a missing regulatory layer in gene transcription. Mao R; Wu Y; Ming Y; Xu Y; Wang S; Chen X; Wang X; Fan Y Sci China Life Sci; 2019 Jul; 62(7):905-912. PubMed ID: 30593613 [TBL] [Abstract][Full Text] [Related]
19. FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature. Saglietti C; Onenerk AM; Faquin WC; Sykiotis GP; Ziadi S; Bongiovanni M Cytopathology; 2017 Dec; 28(6):467-474. PubMed ID: 29094425 [TBL] [Abstract][Full Text] [Related]
20. [KLF6 Super-enhancer Regulates Cell Proliferation by Recruiting GATA2 and SOX10 in Human Hepatoma Cells]. Ri KC; Ryong Ri M; Hun Kim K; Choe SI; Ri JH; Kim JH; Ri JH Mol Biol (Mosk); 2022; 56(3):498-499. PubMed ID: 35621105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]